The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2015 Jul 14

PMID 26166934

Citations 6

Authors

Serhat Gurocak

Ece Konac

Iyimser Ure

Cem Senol

Ilke Hacer Onen

Sinan Sozen

Adnan Menevse

Affiliations

Soon will be listed here.

Abstract

Aim: To determine the impact of gene polymorphisms on detrusor contraction-relaxation harmony in children with lower urinary tract symptoms (LUTS).

Materials And Methods: Toilet trained children older than 5 years of age with LUTS and normal neurological examination underwent videourodynamic study. The control group was composed of age matched children with no voiding complaints. The study group who filled out the voiding dysfunction symptom score before and after the treatment received standard oxybutynin treatment and was reevaluated 1 year after treatment. Genomic DNA was isolated from all patients and subjected to PCR for amplification. Genotyping of ARGHEF10, ROCK2, ADRB3, and CYP3A4 was carried out with Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) method.

Results: 34 (45%) and 42 (55%) patients were enrolled in the study and control group, respectively. ARGEF10 GG, ADRB3 TC, and CYP3A4 AG genotype patients displayed insignificant difference between pre- and posttreatment voiding dysfunction symptom score and bladder volumes.

Conclusions: The polymorphism of genes in the cholinergic pathway did not significantly differ clinical parameters. On the other hand, polymorphic patients in the adrenergic pathway seemed to suffer from clinical disappointment. For this reason, we think that the neglected adrenergic pathway could be a new therapeutic target for the treatment of anticholinergic resistant LUTS in children.

Citing Articles

Association analysis of ADRB3:rs4994 with urodynamic outcome, six months after a single intra-detrusor injection of botulinum toxin, in women with overactive bladder.

Ciecwiez S, Lewandowska K, Szylinska A, Boron A, Kotlega D, Kociszewski J Pharmacol Rep. 2024; 76(6):1489-1500.

PMID: 39259490 PMC: 11582312. DOI: 10.1007/s43440-024-00647-9.

Functional Polymorphism in the Gene, Encoding the Beta-3 Adrenergic Receptor, and Response to Intra-Detrusor Injection of Botulinum Toxin-A in Women with Overactive Bladder.

Ciecwiez S, Lewandowska K, Boron A, Brodowski J, Kociszewski J, Clark J J Clin Med. 2022; 11(24).

PMID: 36556105 PMC: 9781921. DOI: 10.3390/jcm11247491.

Association Between Trp64Arg Polymorphism of Beta-3 Adrenergic Receptor Gene and Susceptibility to Overactive Bladder: A Meta-Analysis.

Dai R, Chen Y, Yang K, Wu T, Deng C Front Genet. 2022; 13:930084.

PMID: 35903356 PMC: 9315387. DOI: 10.3389/fgene.2022.930084.

Genotype and Allele Frequency of in Turkish Patients with Major Depressive Disorder.

Uckun Z, Baskak B, Ozdemir H, Ozel-Kizil E, Devrimci-Ozguven H, Suzen H Turk J Pharm Sci. 2020; 15(2):200-206.

PMID: 32454661 PMC: 7228013. DOI: 10.4274/tjps.46320.

Role of β-3 adrenergic receptor polymorphism in overactive bladder.

Meekins A, Murphy S, Grenier C, Huang Z, Bradley M, Amundsen C Neurourol Urodyn. 2019; 38(5):1261-1265.

PMID: 31009102 PMC: 7216197. DOI: 10.1002/nau.24006.

References

Goessl C, Sauter T, Michael T, Berge B, Staehler M, Miller K . Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000; 55(3):414-8. DOI: 10.1016/s0090-4295(99)00477-x. View

Muller C, Siegmund W, Huupponen R, Kaila T, Franke G, IISALO E . Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Eur J Drug Metab Pharmacokinet. 1993; 18(3):265-72. DOI: 10.1007/BF03188807. View

Leclair M, Heloury Y . Non-neurogenic elimination disorders in children. J Pediatr Urol. 2010; 6(4):338-45. DOI: 10.1016/j.jpurol.2010.01.006. View

Gillam E, Guo Z, Ueng Y, Yamazaki H, Cock I, Reilly P . Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys. 1995; 317(2):374-84. DOI: 10.1006/abbi.1995.1177. View

Boureux A, Vignal E, Faure S, Fort P . Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol. 2006; 24(1):203-16. PMC: 2665304. DOI: 10.1093/molbev/msl145. View

Witte L, Mulder W, de la Rosette J, Michel M . Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?. Curr Opin Urol. 2008; 19(1):13-9. DOI: 10.1097/MOU.0b013e32831a6ff3. View

Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T . Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389(6654):990-4. DOI: 10.1038/40187. View

Yamaguchi O, Chapple C . Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007; 26(6):752-6. DOI: 10.1002/nau.20420. View

Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y . Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000; 101(11):1319-23. DOI: 10.1161/01.cir.101.11.1319. View

10.

Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H . Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol. 2002; 168(3):1247-52. DOI: 10.1016/S0022-5347(05)64634-4. View

11.

Nomiya M, Yamaguchi O . A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003; 170(2 Pt 1):649-53. DOI: 10.1097/01.ju.0000067621.62736.7c. View

12.

Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M . Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001; 11(2):111-21. DOI: 10.1097/00008571-200103000-00002. View

13.

Matsushita T, Ashikawa K, Yonemoto K, Hirakawa Y, Hata J, Amitani H . Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. Hum Mol Genet. 2010; 19(6):1137-46. DOI: 10.1093/hmg/ddp582. View

14.

Honda K, Yamaguchi O, Nomiya M, Shishido K, Ishibashi K, Takahashi N . Association between polymorphism of beta3-adrenoceptor gene and overactive bladder. Neurourol Urodyn. 2013; 33(4):400-2. DOI: 10.1002/nau.22476. View

15.

Yamaguchi O . Beta3-adrenoceptors in human detrusor muscle. Urology. 2002; 59(5 Suppl 1):25-9. DOI: 10.1016/s0090-4295(01)01635-1. View

16.

Yucel S, Akkaya E, Guntekin E, Kukul E, Danisman A, Akman S . Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?. Urology. 2005; 65(2):369-73. DOI: 10.1016/j.urology.2004.09.036. View

17.

Clement K, Vaisse C, Manning B, Basdevant A, Guy-Grand B, Ruiz J . Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 1995; 333(6):352-4. DOI: 10.1056/NEJM199508103330605. View

18.

Zobrist R, Schmid B, Feick A, Quan D, Sanders S . Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001; 18(7):1029-34. DOI: 10.1023/a:1010956832113. View

19.

Franco I . Overactive bladder in children. Part 2: Management. J Urol. 2007; 178(3 Pt 1):769-74. DOI: 10.1016/j.juro.2007.05.076. View

20.

Yaich M, Popon M, Medard Y, Aigrain E . In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998; 8(5):449-51. DOI: 10.1097/00008571-199810000-00010. View